Scpharmaceutical SEC Filings

scPharmaceuticals Inc. (SCPH) reporting person Mette Kirstine Agger, a director, disclosed cancellation and cash-out of certain stock options tied to a merger and tender offer completed on 10/07/2025. Two option grants were disposed: 30,000 options with $3.85 exercise and 19,750 options with $4.11 exercise; both were reported as disposed on 10/07/2025. The filing explains that under the Merger Agreement, options with exercise prices below $5.35 were cancelled and converted into a cash payment equal to the per-share spread times the number of option shares and into one contingent value right (CVR) per option share. The options had expiration dates in 06/03/2035 and 06/11/2034 respectively. The form is a Section 16 disclosure of the changes resulting from the merger terms.

Sara Bonstein, a director of scPharmaceuticals Inc. (SCPH), reported the cancellation on 10/07/2025 of three outstanding stock options totaling 66,050 underlying shares. Each cancelled option was converted under the terms of a Merger Agreement into a cash payment equal to the number of shares covered multiplied by the excess of $5.35 over each option's exercise price, and into one contingent value right (CVR) per share. The cancelled options had exercise prices of $3.85, $4.11, and $4.53 and expiration dates ranging from 06/14/2032 to 06/03/2035

Director Jack A. Khattar reported changes in his holdings following a completed merger transaction. He disposed of 5,000 shares of common stock on 10/07/2025, leaving him with 0 shares of direct common stock. The transactions occurred under a Merger Agreement in which purchasers paid $5.35 per share in cash in a tender offer and issued one non-tradable contingent value right (CVR) per share that may pay up to $1.00 aggregate upon achievement of specified regulatory and net sales milestones. Outstanding company stock options with exercise prices below $5.35 were cancelled and converted into cash payments equal to the excess of $5.35 over the option exercise price, plus one CVR per underlying share; several option grants totaling 72,174 options (aggregate of listed amounts) were reported as disposed/converted.

scPharmaceuticals Inc. filed a post-effective amendment registering additional shares for its employee equity plans. The filing lists a series of previously filed S-8 registrations spanning 2017 through 2025 and shows current registration of 205,000 shares under the Employee Stock Purchase Plan and up to 2,003,827 shares under the 2017 Stock Option and Incentive Plan in the most recent filing. These registrations archive the pool of common stock available for employee awards and recruitment across multiple plan years.

scPharmaceuticals Inc. filed a post-effective amendment to a Form S-8, referencing prior employee equity plan registrations rather than setting out a new offering amount in this excerpt. The filing lists previously registered shares under the company’s equity plans, including the ESPP, the 2017 Stock Option and Incentive Plan, and the 2023 Employment Inducement Award Plan.

Referenced registrations include, most recently, an S-8 filed on March 19, 2025 registering 205,000 shares under the ESPP and 2,003,827 shares under the 2017 Incentive Plan. Additional prior S-8s are cited with their respective amounts for these plans across 2017–2024. These amounts were registered in those earlier S-8 filings and are not newly registered here based on the cited language.

scPharmaceuticals Inc. (SCPH) filed a post-effective amendment on Form S-8 registering employee equity for its plans. The newest registration adds 205,000 shares for the ESPP and 2,003,827 shares for the 2017 Incentive Plan, totaling 2,208,827 newly registered shares under the March 19, 2025 filing. The filing also lists prior S-8 registrations dating back to 2017, showing recurring annual registrations for the ESPP and the 2017 Incentive Plan as well as a 2023 Employment Inducement Award Plan.

This document is a routine securities registration to reserve shares for employee compensation and does not include financial results, transactions, or forward guidance.

scPharmaceuticals Inc. (SCPH) filed a Form S-8 post-effective amendment registering employee equity under multiple plans. The registrant added 205,000 shares for the 2017 Employee Stock Purchase Plan and 2,003,827 shares under the 2017 Stock Option and Incentive Plan in the March 19, 2025 filing, and lists prior S-8 filings from 2017–2024 showing additional ESPP and incentive-plan share pools.

scPharmaceuticals Inc. filed an S-8 post-effective amendment listing multiple prior employee equity registration statements and the share amounts reserved for its employee plans. The filing notes 205,000 shares under the Employee Stock Purchase Plan and up to 2,003,827 shares under the 2017 Stock Option and Incentive Plan (filed March 19, 2025), along with a series of earlier S-8 filings from 2017 through 2024.

scPharmaceuticals filed a post-effective amendment to register employee equity under multiple prior S-8 registrations. The filings list repeated annual registrations of 205,000 shares for the Employee Stock Purchase Plan and varying amounts under the 2017 Stock Option and Incentive Plan, most recently 2,003,827 shares filed March 19, 2025. Earlier S-8 filings from 2017 through 2024 show additional common shares reserved under the 2014 plan, a 2023 Employment Inducement Award Plan (500,000 shares), and annual ESPP allocations.